Human CRTAM Alexa Fluor® 350-conjugated Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: CRTAM

CRTAM (Class I-restricted T cell-associated molecule) is a nectin family member of the immunoglobulin superfamily that is expressed by activated CD8⁺ and NK T cells (1‑4). NK activation receptor engagement, but not cytokines, also induce NK CRTAM expression (4, 5). CRTAM is found in spleen, thymus, small intestine, peripheral blood, and surprisingly, in brain where it is highly expressed by Purkinje cells of the cerebellum (1, 2). Human CRTAM is a 393 amino acid (aa), 80 kDa type I transmembrane glycoprotein with a 17 aa signal sequence, a 269 aa extracellular domain (ECD), a 21 aa transmembrane segment and an 84 aa cytoplasmic domain. The ECD has one V-type and one C1-type Ig-like domain, while the cytoplasmic region shows a potential class I PDZ domain (1‑5). Human CRTAM ECD shows 70%, 43% and 63% aa identity with mouse, rat and canine CRTAM ECD, respectively, but 73‑78% aa identity within the Ig-like domains. The V-type Ig-like domain mediates interaction with the corresponding domain on another nectin family member, IGSF4 (also called TSLC-1, Necl-2, Syncam or SgIGSF) (4, 5). CRTAM is a homodimer on the cell surface but does not show homotypic binding in trans (3‑5). The high affinity of CRTAM/IGSF4 adhesion allows CRTAM to disrupt IGSF4 homotypic interactions (3‑5). IGSF4 and T cell receptor co-engagement of CRTAM-expressing CD8⁺ cells induces increased IFN-gamma or IL-22 production (3, 4). A role in cancer surveillance through NK cell-mediated rejection of IGSF4-expressing tumors has been proposed (3‑5). IGSF4 is expressed broadly, including on epithelia, neurons, a subset of tonsillar B cells (4, 5), and a rare splenic T zone-restricted BCDA3+ dendritic cell population which interacts with CRTAM (3).

Product Datasheets

Product Specific Notices

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

Related Research Areas

• Co-stimulatory and Co-inhibitory Molecules
• Nectin and Nectin-like Binding Receptors and Ligands
• Search Immune Checkpoint Targets